

SUPPLEMENTAL MATERIAL:

Table S1. Baseline characteristics of Patients by NFS and Fibrosis-4

Variables	Non-alcoholic fatty liver disease fibrosis score				Fibrosis-4			
	Low	Intermediate	High	P Value	Low	Intermediate	High	P Value
No. of participants (n =)	230	340	296		182	256	428	
Age, y	52.4±11.4	61.2±12.2	65.6±12.5	0.000	52.1±11.2	62.2±11.4	62.8±13.5	0.000
Female, n (%)	33 (14.3%)	77 (22.6%)	77 (26.0%)	0.005	23 (12.6%)	62 (24.2%)	102 (23.8%)	0.004
Current smokers, n (%)	136 (59.1%)	171 (50.3%)	134 (45.3%)	0.007	108 (59.3%)	121 (47.3%)	212 (49.5%)	0.032
Alcohol consumption, n (%)	52 (22.6%)	61 (17.9%)	56 (18.9%)	0.367	43 (23.6%)	52 (20.3%)	74 (17.3%)	0.182
BMI, kg/m ²	25.5±3.2	25.2±3.8	25.4±3.7	0.418	25.7±3.1	25.4±3.7	25.2±3.8	0.173
Hypertension, n (%)	119 (51.7%)	180 (52.9%)	153 (51.7%)	0.939	96 (52.7%)	148 (57.8%)	208 (48.6%)	0.065
Diabetes mellitus, n (%)	30 (13.0%)	99 (29.1%)	98 (33.1%)	0.000	54 (29.7%)	74 (28.9%)	99 (23.1%)	0.123
Hyperlipidemia, n (%)	54 (23.5%)	90 (26.5%)	88 (29.7%)	0.271	50 (27.5%)	68 (26.6%)	114 (26.6%)	0.973
Chronic kidney disease, n (%)	9 (3.9%)	18 (5.3%)	30 (10.1%)	0.008	11 (6.0%)	14 (1.6%)	32 (3.7%)	0.560
Prior stroke, n (%)	18 (7.8%)	33 (9.7%)	43 (14.5%)	0.034	16 (8.8%)	25 (9.8%)	53 (12.4%)	0.342
Prior bleeding, n (%)	12 (5.2%)	27 (7.9%)	23 (7.8%)	0.410	8 (4.4%)	24 (9.4%)	30 (7.0%)	0.136
Systolic blood pressure, mm Hg	122.2±17.8	122.6±19.5	120.9±19.5	0.523	122.5±17.7	124.2±20.1	120.3±18.9	0.072
Diastolic blood pressure, mm Hg	76.7±11.8	74.2±12.3	72.2±13.2	0.000	75.9±11.1	75.2±13.4	72.8±12.6	0.004
Heart rate, bpm	80.4±14.5	78.4±14.9	79.6±15.4	0.240	79.5±13.3	77.9±14.9	80.1±15.6	0.136
Platelet, 10 ⁹ /L	258.0 (222.8-298.1)	206.0 (175.0-240.0)	184.0 (151.5-217.0)	0.000	253.5 (221.8-294.8)	205.0 (174.0-241.8)	194.0 (159.3-236.0)	0.000
Albumin, g/L	45.0 (42.0-49.0)	42.0 (39.0-44.0)	40.0 (37.1-42.0)	0.000	44.6 (42.0-44.6)	42.0 (40.0-44.4)	44.0 (38.0-43.0)	0.000
ALT, U/L	32.5 (20.0-52.0)	28.0 (18.0-48.0)	37.5 (24.0-59.0)	0.000	28.5 (17.0-42.0)	24.0 (16.0-37.0)	41.0 (26.0-66.8)	0.000
AST, U/L	26.0 (20.0-40.0)	37.5 (22.0-88.8)	138.5 (73.0-240.5)	0.000	21.0 (17.0-28.0)	28.0 (21.0-41.8)	135.0 (80.3-250.5)	0.000
Total bilirubin, umol/L	17.0 (9.8-31.3)	13.9 (8.8-21.0)	15.3 (10.8-21.7)	0.004	15.7 (9.0-28.0)	13.6 (8.6-22.1)	15.3 (11.2-22.0)	0.035
GGT, U/L	23.9 (12.1-40.3)	24.0 (15.0-39.0)	20.0 (14.0-30.0)	0.061	23.0 (12.3-38.0)	22.1 (14.0-34.0)	22.0 (14.1-37.5)	0.662
Creatinine, mg/dL	0.82 (0.70-0.96)	0.84 (0.71-0.97)	0.83 (0.71-1.03)	0.559	0.82 (0.69-0.95)	0.83 (0.70-0.98)	0.84 (0.73-0.98)	0.345
Triglycerides, mmol/L	1.7 (1.3-2.6)	1.5 (1.1-3.0)	1.3 (0.9-1.9)	0.000	1.7 (1.3-2.7)	1.5 (1.1-2.1)	1.4 (1.0-2.0)	0.000
Total cholesterol, mmol/L	4.9 (4.2-5.7)	4.6 (3.9-5.3)	4.6 (3.9-5.2)	0.000	4.8 (4.1-5.6)	4.7 (3.8-5.5)	4.7 (3.9-5.3)	0.042
LDL-C, mmol/L	3.1 (2.7-3.8)	2.9 (2.3-3.5)	2.9 (2.4-3.4)	0.000	3.1 (2.6-3.8)	3.0 (2.3-3.5)	2.9 (2.4-3.4)	0.009

HDL-C, mmol/L	0.96 (0.77-1.16)	0.97 (0.81-1.15)	1.00 (0.85-1.19)	0.189	0.90 (0.78-1.12)	0.96 (0.79-1.16)	1.00 (0.85-1.19)	0.008
Lp(a), mg/L	112.4 (45.2-242.0)	116.1 (51.1-262.3)	102.8 (53.5-241.7)	0.868	112.4 (47.6-259.7)	114.3 (47.2-253.0)	105.0 (53.6-247.4)	0.968
HbA1c, %	5.8 (5.5-6.4)	5.9 (5.6-6.9)	6.0 (5.6-7.1)	0.016	5.9 (5.5-7.2)	5.9 (5.5-6.8)	5.9 (5.6-6.6)	0.331
D-Dimer, mg/L	0.31 (0.24-0.46)	0.35 (0.25-0.60)	0.41 (0.28-0.80)	0.000	0.31 (0.23-0.47)	0.35 (0.25-0.59)	0.39 (0.27-0.70)	0.000
peak value of TnT, ng/ml	3.52 (1.13-6.44)	3.37 (1.44-6.40)	4.82 (3.11-7.78)	0.000	3.69 (0.83-6.14)	2.65 (1.18-6.34)	4.87 (2.78-7.60)	0.000
peak value of TnI, ng/ml	0.49 (0.05-3.76)	0.82 (0.05-4.56)	1.26 (0.06-6.47)	0.281	0.54 (0.05-3.79)	0.73 (0.05-4.15)	1.15 (0.07-5.68)	0.185
Peak TnT/TnI>10ULN	126 (54.8%)	189 (55.6%)	191 (64.5%)	0.031	93 (51.1%)	130 (50.8%)	283 (66.1%)	0.000
peak value of NT-proBNP, pg/ml	980.0 (550.0-2250.0)	1482.0 (651.0-3186.5)	2282.0 (1134.0-4548.0)	0.000	839.0 (448.5-1800.3)	1301.5 (601.0-3030.5)	2100.0 (997.5-4230.5)	0.000
peak value of BNP, ng/ml	105.0 (22.0-234.0)	178.6 (60.7-479.0)	219.2 (67.9-543.0)	0.001	90.8 (21.7-234.3)	171.5 (34.8-417.3)	191.0 (67.9-543.0)	0.004
Peak BNP/NT-proBNP>10ULN	5 (2.2%)	22 (6.5%)	22 (7.4%)	0.025	6 (3.3%)	17 (6.6%)	26 (6.1%)	0.286
LVEF, %	61.0 (55.0-67.0)	60.0 (52.0-65.0)	55.0 (47.3-63.0)	0.000	61.0 (55.0-67.0)	60.0 (52.0-66.0)	57.0 (48.0-64.0)	0.000
Gensini Score	56.0(37.0-82.0)	51.3(37.0-80.0)	54.0(40.0-81.5)	0.458	56.0(37.0-82.0)	50.0(37.0-80.0)	57.0(40.0-82.0)	0.124
Killip class				0.001				0.024
1	194 (84.3%)	246 (72.4%)	208 (70.3%)		154 (84.6%)	189 (73.8%)	305 (71.3%)	
2	14 (6.1%)	47 (13.8%)	38 (12.8%)		15 (8.2%)	31 (12.1%)	53 (12.4%)	
3	5 (2.2%)	5 (1.5%)	15 (5.1%)		2 (1.1%)	10 (3.9%)	13 (3.0%)	
4	17 (7.4%)	42 (12.4%)	35 (11.8%)		11 (6.0%)	26 (10.2%)	57 (13.3%)	
Aspirin, n (%)	230 (100%)	340 (100%)	296 (100%)	-	182 (100%)	256 (100%)	428 (100%)	
Clopidogrel, n (%)	132 (57.4%)	248 (72.9%)	222 (75.0%)	0.000	103 (56.6%)	180 (70.3%)	319 (74.5%)	0.000
Ticagrelor, n (%)	98 (42.6%)	93 (27.4%)	74 (25.0%)	0.000	79 (43.4%)	76 (29.7%)	110 (41.5%)	0.000
ACEI/ARB, n (%)	192 (83.5%)	276 (81.2%)	215 (72.6%)	0.004	149 (81.9%)	207 (80.9%)	327 (76.4%)	0.207
Beta-blockers, n (%)	218 (94.8%)	315 (92.6%)	273 (92.2%)	0.481	177 (97.3%)	233 (91.0%)	396 (92.5%)	0.033
CCB, n (%)	9 (3.9%)	13 (3.8%)	11 (3.7%)	0.993	11 (6.0%)	11 (4.3%)	11 (2.6%)	0.109
Statins, n (%)	225 (97.8%)	332 (97.6%)	290 (98.0%)	0.961	179 (94.4%)	252 (98.4%)	416 (97.2%)	0.480
Diuretics, n (%)	22 (9.6%)	46 (13.5%)	43 (14.5%)	0.212	17 (9.3%)	33 (12.9%)	61 (14.3%)	0.252
PPI, n (%)	140 (60.9%)	208 (61.2%)	188 (63.5%)	0.777	111 (61.0%)	152 (59.4%)	273 (63.8%)	0.496

Continuous values are summarized as mean±SD, median (interquartile range) and categorical variables as number (percentage). BMI indicates body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, Gamma-glutamyltransferase; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; ULN, Upper limit of normal; LVEF, Left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitor; NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4.

Table S2. Baseline characteristics of Patients by BARD and Forns

Variables	BARD				Forns			
	Low	Intermediate	High	<i>P</i> Value	Low	Intermediate	High	<i>P</i> Value
No. of participants (n =)	127	446	293		238	498	114	
Age, y	52.7±10.9	62.4±13.1	60.6±12.9	0.000	50.5±10.9	62.9±11.6	70.3±11.5	0.000
Female, n (%)	13 (10.2%)	111 (24.9%)	63 (7.3%)	0.002	35 (14.7%)	122 (24.5%)	27 (23.7%)	0.009
Current smokers, n (%)	70 (55.1%)	219 (49.1%)	152 (51.9%)	0.451	144 (60.5%)	242 (48.6%)	47 (41.2%)	0.001
Alcohol consumption, n (%)	23 (18.1%)	92 (20.6%)	54 (18.4%)	0.694	41 (17.2%)	102 (20.5%)	23 (20.2%)	0.571
BMI, kg/m ²	26.1±3.0	23.9±2.6	27.3±4.1	0.000	26.1±3.4	25.2±3.7	24.5±3.7	0.000
Hypertension, n (%)	60 (47.2%)	213 (47.8%)	179 (61.1%)	0.001	118 (49.6%)	261 (52.4%)	67 (58.8%)	0.271
Diabetes mellitus, n (%)	34 (26.8%)	8 (1.8%)	185 (63.1%)	0.000	45 (18.9%)	141 (28.3%)	37 (32.5%)	0.007
Hyperlipidemia, n (%)	38 (29.9%)	97 (21.7%)	97 (33.1%)	0.002	63 (26.5%)	128 (25.7%)	35 (30.7%)	0.552
Chronic kidney disease, n (%)	6 (4.7%)	30 (6.7%)	21 (7.2%)	0.640	9 (3.8%)	31 (6.2%)	16 (14.0%)	0.001
Prior stroke, n (%)	9 (7.1%)	48 (10.8%)	37 (12.6%)	0.244	20 (8.4%)	50 (10.0%)	24 (21.1%)	0.001
Prior bleeding, n (%)	5 (3.9%)	39 (8.7%)	18 (6.1%)	0.127	12 (5.0%)	36 (7.2%)	14 (12.3%)	0.050
Systolic blood pressure, mm Hg	121.4±17.6	120.5±18.7	124.2±20.1	0.831	124.3±18.8	121.4±19.1	118.8±19.5	0.053
Diastolic blood pressure, mm Hg	75.3±11.5	73.3±12.3	75.1±13.4	0.067	78.6±12.0	73.2±12.4	69.6±12.0	0.000
Heart rate, bpm	80.8±14.3	78.0±14.7	80.7±15.5	0.037	81.6±13.7	77.9±14.5	80.8±18.6	0.005
Platelet, 10 ⁹ /L	226.0 (185.0-268.0)	205.5 (172.0-249.0)	212.0 (174.5-246.5)	0.001	230.0 (213.7-264.5)	202.0 (176.0-233.0)	145.0 (128.0-170.50)	0.000
Albumin, g/L	45.0 (42.0-46.0)	41.0 (38.7-44.0)	41.1 (38.6-44.0)	0.000	44.0 (41.0-46.8)	41.4 (38.8-44.0)	40.0 (37.4-42.0)	0.000
ALT, U/L	39.0 (30.0-59.0)	29.0 (19.0-52.0)	33.0 (20.0-51.5)	0.000	35.0 (21.0-58.0)	30.0 (20.0-48.3)	35.5 (20.0-58.3)	0.072
AST, U/L	23.0 (20.0-32.0)	61.0 (27.0-173.0)	60.0 (27.0-142.0)	0.000	39.5 (23.0-142.0)	49.5 (23.0-130.0)	61.5 (25.8-150.3)	0.226
Total bilirubin, umol/L	15.4 (9.5-28.0)	14.7 (10.2-22.3)	15.3 (9.5-23.0)	0.389	19.4 (11.2-34.0)	14.0 (9.3-20.0)	13.3 (9.6-19.8)	0.000
GGT, U/L	29.0 (16.3-48.0)	19.0 (13.0-33.0)	23.0 (15.1-37.0)	0.000	17.0 (10.5-29.0)	23.0 (15.0-35.3)	32.0 (16.9-61.5)	0.000
Creatinine, mg/dL	0.83 (0.70-1.00)	0.82 (0.71-0.96)	0.84 (0.70-1.0)	0.291	0.81 (0.71-0.93)	0.84 (0.70-0.98)	0.85 (0.73-1.12)	0.062
Triglycerides, mmol/L	1.75 (1.33-2.64)	1.34 (0.96-1.97)	1.57 (1.06-2.28)	0.000	1.73 (1.29-2.60)	1.42 (1.00-2.10)	1.09 (0.75-1.60)	0.000
Total cholesterol, mmol/L	4.78 (4.06-6.65)	4.70 (3.98-5.42)	4.62 (3.87-5.21)	0.296	5.30 (4.70-6.13)	4.52 (3.91-5.15)	3.88 (3.21-4.58)	0.000
LDL-C, mmol/L	3.12 (2.47-3.78)	2.98 (2.43-3.53)	2.91 (2.35-3.40)	0.183	3.47 (2.98-4.07)	2.87 (2.38-3.35)	2.28 (1.92-2.91)	0.000

HDL-C, mmol/L	0.88 (0.75-1.11)	1.02 (0.86-1.24)	0.93 (0.79-1.09)	0.000	1.04 (0.86-1.21)	0.95 (0.79-1.17)	0.97 (0.80-1.10)	0.002
Lp(a), mg/L	114.2 (44.1-266.1)	110.9 (53.3-247.6)	101.5 (46.0-243.0)	0.724	117.1 (49.4-234.2)	108.6 (52.0-268.5)	107.7 (51.2-260.6)	0.891
HbA1c, %	5.9 (5.5-7.2)	5.8 (5.5-6.1)	6.6 (5.8-8.0)	0.000	5.8 (5.5-6.5)	5.9 (5.6-6.9)	5.9 (5.6-7.0)	0.278
D-Dimer, mg/L	0.28 (0.22-0.38)	0.36 (0.26-0.58)	0.39 (0.26-0.82)	0.000	0.30 (0.23-0.42)	0.37 (0.26-0.66)	0.50 (0.32-0.90)	0.000
peak value of TnT, ng/ml	3.37 (1.02-6.02)	4.45 (2.16-7.29)	4.14 (1.70-6.84)	0.012	3.67 (1.36-6.44)	4.50 (1.96-7.23)	3.97 (2.31-6.70)	0.106
peak value of TnI, ng/ml	1.03 (0.05-5.10)	0.91 (0.05-5.33)	0.76 (0.05-4.90)	0.813	1.25 (0.05-6.32)	0.72 (0.05-4.71)	1.39 (0.14-6.27)	0.293
Peak TnT/TnI>10ULN	72 (56.7%)	265 (59.4%)	169 (57.7%)	0.817	146 (61.3%)	288 (57.8%)	64 (56.1%)	0.564
peak value of NT-proBNP, pg/ml	825.0 (388.3-1724.5)	1664.0 (860.5-3294.5)	1638.0 (694.3-4264.0)	0.000	862.0 (538.0-1811.0)	1817.0 (916.0-3681.0)	2956.0 (1154.0-5562.0)	0.000
peak value of BNP, ng/ml	105.0 (24.8-231.0)	179.0 (60.4-570.3)	180.0 (52.5-441.0)	0.011	111.0 (26.8-230.0)	149.0 (49.5-387.2)	441.0 (187.0-897.0)	0.000
Peak BNP/NT-proBNP>10ULN	0 (0%)	29 (6.5%)	20 (6.8%)	0.011	7 (2.9%)	25 (5.0%)	16 (14.0%)	
LVEF, %	61.0 (55.0-68.0)	59.0 (50.0-65.0)	58.0 (50.0-65.0)	0.003	60.0 (54.0-67.0)	59.0 (50.0-65.0)	56.0 (45.0-63.0)	0.001
Gensini Score	52.0(38.5-80.0)	52.0(38.0-81.0)	54.0(40.0-82.0)	0.612	52.0(37.0-84.0)	56.0(39.0-80.0)	47.0(38.5-82.0)	0.564
Killip class				0.047				0.000
1	105 (82.7%)	334 (74.9%)	209 (71.3%)		206 (86.6%)	357 (71.7%)	71 (62.3%)	
2	11 (8.7%)	47 (47.5%)	41 (41.4%)		15 (6.3%)	65 (13.1%)	19 (16.7%)	
3	1 (0.8%)	10 (2.2%)	14 (4.8%)		4 (1.7%)	16 (3.2%)	5 (4.4%)	
4	10 (10.6%)	55 (58.5%)	29 (30.9%)		13 (5.5%)	60 (12.0%)	19 (16.7%)	
Aspirin, n (%)	127 (100%)	446 (100%)	293 (100%)	-	238 (100%)	498 (100%)	114 (100%)	
Clopidogrel, n (%)	69 (54.3%)	313 (70.2%)	220 (75.1%)	0.000	125 (52.5%)	367 (73.7%)	95 (83.3%)	0.000
Ticagrelor, n (%)	58 (45.7%)	134 (30.0%)	73 (24.9%)	0.000	113 (47.5%)	132 (26.5%)	95 (16.7%)	0.000
ACEI/ARB, n (%)	104 (81.9%)	340 (76.2%)	239 (81.6%)	0.147	200 (84.0%)	388 (77.9%)	82 (71.9%)	0.025
Beta-blockers, n (%)	122 (96.1%)	404 (90.6%)	280 (95.6%)	0.012	227 (95.4%)	465 (93.4%)	98 (86.0%)	0.005
CCB, n (%)	5 (3.9%)	11 (2.5%)	17 (5.8%)	0.068	6 (2.5%)	21 (4.2%)	6 (5.3%)	0.384
Statins, n (%)	125 (98.4%)	436 (97.8%)	286 (97.6%)	0.868	237 (99.6%)	483 (97.0%)	114 (100.0%)	0.015
Diuretics, n (%)	9 (7.1%)	63 (14.1%)	39 (13.3%)	0.106	26 (10.9%)	59 (11.8%)	26 (22.8%)	0.004
PPI, n (%)	76 (59.8%)	288 (64.6%)	172 (58.7%)	0.241	146 (61.3%)	301 (60.4%)	81 (71.1%)	0.104

Continuous values are summarized as mean±SD, median (interquartile range) and categorical variables as number (percentage). BMI indicates body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, Gamma-glutamyltransferase; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; ULN, Upper limit of normal; LVEF, Left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitor; BARD indicates body mass index, AST/ALT ratio, diabetes mellitus score.

Table S3. Liver fibrosis scores of patients with single or multiple diseased vessels

	Single	Multiple	<i>P</i> Value
NFS	-0.32(-1.59-1.40)	-0.24(-1.50-1.23)	0.904
FIB-4	3.01(1.52-6.56)	2.57(1.36-5.61)	0.320
BARD	-	-	0.361
Forns score	5.33(4.03-6.34)	5.24(4.07-6.23)	0.649
NFS			0.311
Low	45(19.6%)	185(80.4%)	
Intermediate	54(15.9%)	286(84.1%)	
High	60(20.3%)	236(79.7%)	
FIB-4			0.327
Low	29(15.9%)	153(84.1%)	
Intermediate	43(16.8%)	213(83.2%)	
High	87(20.3%)	341(79.7%)	
BARD			0.462
Low	27(21.3%)	100(78.7%)	
Intermediate	84(18.8%)	362(81.2%)	
High	48(16.4%)	245(83.6%)	
Forns score			0.507
Low	43(18.1%)	195(81.9%)	
Intermediate	86(17.3%)	412(82.7%)	
High	25(21.9%)	89(78.1%)	

NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4; BARD, body mass index, AST/ALT ratio, diabetes mellitus score.

Table S4. Univariate Cox Regression Analysis for the MACEs Among STEMI Patients

Variables	Hazard Ratio (95% CI)	P Value
Female	1.732(1.232-2.435)	0.002
Current smoking	0.475(0.341-0.661)	0.000
Prior stroke	1.922(1.269-2.912)	0.002
Chronic kidney disease	3.110(1.977-4.891)	0.000
Diastolic blood pressure	0.973(0.960-0.986)	0.000
LVEF	0.984(0.969-1.000)	0.048
Killip class		
1	Ref	
2	2.140(1.420-3.227)	0.000
3	2.170(1.006-4.678)	0.048
4	1.740(1.103-2.745)	0.017
Creatinine	1.179(1.091-1.275)	0.000
D-D	1.080(1.021-1.142)	0.007
Peak TnT/TnI>10ULN	1.463(1.052-2.035)	0.024
Peak BNP/NT-proBNP>10ULN	2.203(1.347-3.602)	0.002
Ticagrelor	0.950(0.652-1.384)	0.788
ACEI/ARB	0.529(0.375-0.746)	0.000
Beta-blockers	0.500(0.302-0.829)	0.007
Diuretics	1.974(1.338-2.914)	0.001
PPI	1.447(1.032-2.029)	0.032
NFS		
Per 1-SD	1.145(1.068-1.228)	0.000
Low risk	Ref	
Intermediate risk	1.407(0.891-2.222)	0.143
High risk	2.026(1.300-3.159)	0.002
FIB-4		
Per 1-SD	1.035(1.008-1.064)	0.012
Low risk	Ref	
Intermediate risk	2.026(1.165-3.523)	0.012
High risk	2.299(1.369-3.861)	0.002
BARD		
Per 1-point	1.243(1.035-1.493)	0.020
Low risk	Ref	
Intermediate risk	3.429(1.664-7.064)	0.001
High risk	3.056(1.457-6.411)	0.003
Forns		
Per 1-SD	1.378(1.244-1.526)	0.000
Low risk	Ref	
Intermediate risk	1.923(1.208-3.060)	0.006

High risk	3.407(2.004-5.793)	0.000
-----------	--------------------	-------

LVEF indicates left ventricular ejection fraction; ULN, Upper limit of normal; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitor; NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4 ; BARD, body mass index, AST/ALT ratio, diabetes mellitus score.

Table S5. Subgroup analyses of Liver Fibrosis Scores for predicting MACEs

Subgroup	Events/Subjects	Adjusted hazard ratio of highest vs. lowest group (95% CI) and <i>P</i> Value for interaction				
Age≥65, yrs		NFS	FIB-4	BARD	Forns	
			0.705	0.732	0.870	0.030
Yes	94/311	0.87 (0.39-1.89)	1.87 (0.56-6.22)	2.71 (0.63-11.70)	0.83 (0.36-1.92)	
No	61/555	0.86 (0.41-1.82)	1.38 (0.66-2.89)	2.08 (0.82-5.28)	2.95 (1.07-8.17)	
Sex			0.130	0.159	0.283	0.064
Men	107/679	1.58 (0.87-2.85)	2.22 (1.10-4.50)	2.75 (1.14-6.63)	3.04 (1.50-6.15)	
Women	48/187	1.05 (0.42-2.66)	1.33 (0.49-3.63)	1.24 (0.26-5.89)	1.12 (0.33-3.78)	
Diabetes			0.389	0.437	0.970	0.303
Yes	49/227	1.29 (0.44-3.83)	1.96 (0.75-5.15)	2.71 (0.78-9.45)	1.13 (0.35-3.70)	
No	106/639	1.39 (0.79-2.45)	2.40 (1.04-5.51)	2.07 (0.73-5.86)	2.87 (1.42-5.79)	
BMI			0.825	0.822	0.709	0.433
≥28kg/m ²	25/185	0.71 (0.18-2.87)	1.55 (0.37-6.53)	1.34 (0.27-6.76)	2.16 (0.30-15.28)	
<28kg/m ²	130/681	1.43 (0.82-2.47)	2.05 (1.07-3.93)	2.95 (1.20-7.24)	2.17 (1.13-4.15)	
The number of diseased vessels			0.796	0.692	0.253	0.148
Single	18/159	2.42 (0.55-10.69)	3.40 (0.53-21.63)	2.62 (0.17-39.36)	0.227 (0.01-4.61)	
Multiple	137/707	1.31 (0.76-2.27)	2.01 (1.07-3.79)	2.81 (1.18-6.70)	2.835 (1.47-5.46)	

The adjusted model included sex, current smoking, prior stroke, chronic kidney disease, diastolic blood pressure, LVEF, Killip class, creatinine, D-Dimer, peak TnT/TnI>10ULN, peak BNP/NT-proBNP>10ULN, baseline use of ticagrelor, ACEI/ARB, Beta-blockers, diuretics, PPI, other than the variables included in the score formula.

NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4; BARD, body mass index, AST/ALT ratio, diabetes mellitus score; LVEF, left ventricular ejection fraction; ULN, Upper limit of normal; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitor

Table S6. Baseline characteristics compared between patients with and without CT/ultrasound

Variables	Patients without CT/ultrasound (n=494)	Patients with CT/ultrasound (n=372)	P Value
Age, y	60.6±13.2	60.0±13.0	0.501
Female, n (%)	112 (22.7%)	75 (20.2%)	0.374
Current smokers, n (%)	250 (50.6%)	191 (51.3%)	0.830
Alcohol consumption, n (%)	93 (18.8%)	76 (20.4%)	0.555
BMI,kg/m ²	25.3±3.7	25.4±3.6	0.924
Hypertension, n (%)	264 (53.4%)	188 (50.5%)	0.397
Diabetes mellitus, n (%)	126 (25.5%)	101 (27.2%)	0.586
Hyperlipidemia, n (%)	136 (27.5%)	96 (25.8%)	0.571
Chronic heart failure, n (%)	5 (1.0%)	0 (0.0%)	0.052
Chronic kidney disease, n (%)	36 (7.3%)	21 (5.6%)	0.335
Hemodialysis	4 (0.8%)	4 (1.1%)	0.171
Prior stroke, n (%)	59 (11.9%)	35 (9.4%)	0.235
Prior bleeding, n (%)	39 (7.9%)	23 (6.2%)	0.333
Systolic blood pressure, mm Hg	122.2±18.9	121.5±19.3	0.576
Diastolic blood pressure, mm Hg	74.2±12.3	74.1±13.0	0.908
Heart rate	79.2±15.2	79.5±14.6	0.812
Platelet,10 ⁹ /L	215.0(178.0-249.5)	205.0(168.3-250.0)	0.423
Albumin, g/L	42.0(39.0-45.0)	42.0(39.0-44.0)	0.762
ALT, U/L	33.0(21.0-51.0)	31.50(19.0-53.75)	0.563
AST, U/L	48.0(24.0-135.0)	46.0(22.0-148.3)	0.763
Total bilirubin, umol/L	14.5(9.6-22.1)	13.2(9.0-18.5)	0.001
Gamma-glutamyltransferase, U/L	23.0(15.0-39.0)	25.0(16.0-39.0)	0.005
Creatinine, mg/dL	0.8(0.7-1.0)	0.8(0.7-1.0)	0.484
Triglycerides, mmol/L	1.5(1.1-2.2)	1.4(1.0-2.1)	0.457
Total cholesterol, mmol/L	4.7(4.0-5.4)	4.6(3.9-5.3)	0.220
D-D, mg/L	0.4(0.2-0.8)	0.3(0.2-0.6)	0.273
Nonalcoholic fatty liver disease fibrosis score	-0.3(-1.5-1.0)	-0.1(-1.6-1.3)	0.368
Fibrosis-4	2.6(1.4-5.6)	2.8(1.4-6.5)	0.515
BMI, AST/ALT ratio, diabetes mellitus score	2.0(2.0-3.0)	2.0(2.0-3.0)	0.194
Forns score	5.3(4.1-6.3)	5.4(4.2-6.4)	0.177


Table S7. Sensitivity Analysis of the association between Liver fibrosis scores and MACEs in Patients with NAFLD and without NAFLD

Liver fibrosis scores	NAFLD (n=180)		Without NAFLD(n=192)		<i>P</i> Value for interaction
	MACEs (%)	Hazard Ratio (95% CI)	MACEs (%)	Hazard Ratio (95% CI)	
NFS risk category					0.692
Low	4(6.3%)	Ref	7(18.4%)	Ref	
Intermediate	11(18.3%)	2.327(0.695-7.784)	17(22.1%)	0.800(0.279-2.293)	
High	14(24.6%)	4.075(1.263-13.154)	21(27.3%)	0.698(0.237-2.054)	
FIB-4 risk category					0.426
Low	6(11.3%)	Ref	2(8.3%)	Ref	
Intermediate	7(15.6%)	1.357(0.416-4.424)	15(24.6%)	9.453(0.873-102.353)	
High	16(19.5%)	1.894(0.686-5.232)	28(26.2%)	7.356(0.739-73.255)	
BARD risk category					0.328
Low	2(5.7%)	Ref	0(0.0%)	-	
Intermediate	15(20.3%)	4.395(0.964-20.027)	31(25.2%)	Ref	
High	12(16.9%)	3.047(0.639-14.529)	14(24.1%)	0.817(0.387-1.724)	
Forns risk category					0.396
Low	5(8.1%)	Ref	3(9.1%)	Ref	
Intermediate	15(16.0%)	1.633(0.557-4.790)	29(24.8%)	1.430(0.402-5.095)	
High	8(40.0%)	4.849(1.268-18.538)	13(36.1%)	1.080(0.258-4.533)	

The adjusted model included sex, current smoking, prior stroke, chronic kidney disease, diastolic blood pressure, LVEF, Killip class, creatinine, D-Dimer, peak TnT/TnI>10ULN, peak BNP/NT-proBNP>10ULN, baseline use of ticagrelor, ACEI/ARB, Beta-blockers, diuretics, PPI, other than the variables included in the score formula.

NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4; BARD, body mass index, AST/ALT ratio, diabetes mellitus score; LVEF, left ventricular ejection fraction; ULN, Upper limit of normal; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitor

Figure S1. The incidence rate of MACEs in different Liver Fibrosis Scores group.



NFS indicates nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4; BARD, body mass index, AST/ALT ratio, diabetes mellitus score; # $P<0.0167$, Low risk group vs Intermediate risk group; * $P<0.0167$, Low risk group vs High risk group; & $P<0.0167$, Intermediate risk group vs High risk group